Global Next Generation Sequencing (NGS) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Next Generation Sequencing (NGS) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionized the study of genomics and molecular biology.

Market Overview:

The latest research study on the global Next Generation Sequencing (NGS) market finds that the global Next Generation Sequencing (NGS) market reached a value of USD 10598.09 million in 2022. It’s expected that the market will achieve USD 21042.33 million by 2028, exhibiting a CAGR of 12.11% during the forecast period.

Impacts from the short-term

With the spread of the novel coronavirus pneumonia epidemic globally, the World Health Organization has classified the novel coronavirus pneumonia epidemic as a global pandemic. This epidemic has brought severe challenges to the public health undertakings of all countries, as well as a major economic problem, which inevitably caused negative effects. However, COVID-19 has objectively improved the infection prevention and control business of the next-generation sequencing company, and can test the company's efficient operation capabilities. In order to cope with the negative impact of the epidemic, next-generation sequencing companies will adopt a variety of methods to promote the rapid normalization of major business areas, maintain and fulfill the normal needs of customers during the epidemic, and minimize adverse effects.

Impacts from the long-term

In the long run, many next-generation sequencing companies are accelerating the development of new coronavirus detection reagents. Relying on the accumulation of profound experience in the field of infection prevention and control, the next-generation sequencing company uses genomics to discover genetic factors that are susceptible to COVID-19. This groundbreaking human genome study will help explain why some COVID-19 patients are mildly infected, while others require intensive care. The research and development of this technology has promoted the development of the next-generation sequencing market.

Growing demand for early diagnosis of genetic disorders

The need to prevent physical disabilities and health conditions in newborns is increasing the demand for early diagnosis among expecting parents. Pre-implantation diagnostic tests facilitate the determination of genetic disorders, such as cystic fibrosis, congenital hearing loss, and thalassemia. Thus, parents are increasingly opting for preimplantation testing, which increases the adoption of NGS techniques. Sequencing technology allows for a simple PGS workflow with flexible sample throughput for consistent and quick aneuploidy detection.

Workflow and data analysis related challenges

The lack of universal computer software tools is considered the main limiting factor in NGS data analysis and interpretation. Currently, industry stakeholders are actively collaborating to integrate their respective resources to mine these huge and complex data sets to generate actionable insights relevant to the clinic. In addition, there is a need for a better genomic library preparation scheme, which requires less starting material, and can generate a library with a more accurate estimate of the insert size and a longer read rate, with a reduced error rate. More efficient genome assembly algorithms and better processors (increased computing power) for genome data processing may also be developed. Once the above challenges are solved, the Next Generation Sequencing market in the biopharmaceutical industry will achieve significant growth.

Region Overview:

In global comparison, a significant portion of the revenue was generated in North America (43.53% in 2021).

Company Overview:

Illumina is one of the major players operating in the Next Generation Sequencing (NGS) market, holding a share of 43.11% in 2022.

Illumina

Illumina is an American biotechnology company, founded in 1998 and headquartered in San Diego, California. The company specializes in bioinformatics analysis and provides services related to SNP genotyping, copy number variation (CNV), genome sequencing, DNA methylation research, transcriptome analysis, and gene expression profiling.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is an American biotechnology and medical device company. Thermo Fisher Scientific Inc. mainly produces laboratory equipment, reagents, analytical instruments, consumables and software.

Segmentation Overview:

Among different product types, Consumables segment is anticipated to contribute the largest market share in 2027.

Consumables

The consumables for next-generation sequencing are mainly card readers, deep well plates, pipettes, pipettes, vials and other instruments with high precision, which are often needed during experiments. Moreover, they are disposable, and therefore have a significant replacement rate, which drives their adoption.

Platforms

Many different platforms based on next-generation sequencing technology can be used for a variety of sequencing, the platform can provide high-throughput sequencing, and can provide greater flexibility and scalability for various project types.

Services

Next-generation Sequencing Services is a powerful tool for observing the genetic map of the organisms selected by customers. Look for SNP variants or pathogenic loci that are the basis of the customer's favorite phenotype. Determine how drug manipulation affects the expression of coding regions in the genome. Discover novel transcripts and even explore the genetic makeup of previously unmapped organisms.

Sequencing Services

Next-generation sequencing (NGS) services include RNA and whole-genome sequencing services. By cooperating with certified sequencing service providers and providing consulting services to help customers complete the sequencing workflow.

Bioinformatics

Next Generation Sequencing (NGS) technologies offer high-throughput, rapid and accurate methods of determining the precise order of nucleotides within DNA/RNA molecules. Correspondingly, the field of bioinformatics is central to the interpretation and application of this biological data.

Application Overview:

The market's largest segment by application is the segment Hospitals and Clinics, with a market share of 42.88% in 2021.

Academic and Clinical Research Centers

Extensive experiments and research conducted in academic and clinical research centers, using Next Generation Sequencing to develop new therapies. For example, third-generation sequencing methods are used to detect germline or somatic mutations, enabling scientists to effectively perform clinical analysis. Genetic analysis and other research activities can be accomplished by using single-gene and multi-gene panels with higher specificity.

Pharmaceutical and Biotechnology Companies

Next Generation Sequencing can provide customized solutions that allow customers to customize their diagnostic requirements across multiple platforms and chemical options to suit their specific translation research or clinical trial needs. NGS analysis tools have helped pharmaceutical and biopharmaceutical companies design treatments based on the nature of the disease.

Hospitals and Clinics

NGS is widely used in hospitals and clinics to diagnose immune diseases, infectious diseases, non-invasive prenatal diagnosis and detection of human genetic diseases. It can help healthcare professionals make treatment decisions about body cancer.

Key Companies in the global Next Generation Sequencing (NGS) market covered in Chapter 3:

Pacific Biosciences of California
Macrogen
Eurofins Scientific
Perkinelmer
Illumina
Genomatix (Precigen)
BGI Group
Oxford Nanopore Technologies
Qiagen N.V.
10x Genomics
GENEWIZ
Agilent Technologies
Thermo Fisher Scientific
Hamilton Company
PierianDx

In Chapter 4 and Chapter 14.2, on the basis of types, the Next Generation Sequencing (NGS) market from 2018 to 2029 is primarily split into:

Consumables
Platforms
Services
Sequencing Services
Bioinformatics

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Next Generation Sequencing (NGS) market from 2018 to 2029 covers:

Academic and Clinical Research Centers
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)